Evidence map›Paper›PMID 42737752›Full record

ArticleInternational journal of molecular sciences2026

Kaiso Is a Novel TAZ-Interaction Partner That Promotes Hepatic Stellate Cell Activation and Regulates the Downstream lncRNA HIF1A-AS3.

Amira Khaled Abdelhamid, Fabiola Pedrini, Jennifer Schmitt, Ibrahim Hassan Fayed, Aya Osama, Hannah H Rashwan, Diana M F Hanna, Esther T Menze, Sameh Magdeldin, Marcin Luzarowski and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Amira Khaled AbdelhamidSchool of Medicine, Newgiza University (NGU), Giza 12577, Egypt.
Fabiola PedriniInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Jennifer SchmittInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Ibrahim Hassan FayedSchool of Medicine, Newgiza University (NGU), Giza 12577, Egypt.ORCID 0009-0008-1688-1128
Aya OsamaProteomics and Metabolomics Research Program, Research Department, Children's Cancer Hospital Egypt 57357 (CCHE-57357), Cairo 11562, Egypt.ORCID 0000-0003-1345-010X
Hannah H RashwanProteomics and Metabolomics Research Program, Research Department, Children's Cancer Hospital Egypt 57357 (CCHE-57357), Cairo 11562, Egypt.
Diana M F HannaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.
Esther T MenzeDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.
Sameh MagdeldinProteomics and Metabolomics Research Program, Research Department, Children's Cancer Hospital Egypt 57357 (CCHE-57357), Cairo 11562, Egypt.ORCID 0000-0002-7507-9935
Marcin LuzarowskiCore Facility for Mass Spectrometry and Proteomics, Center for Molecular Biology, Heidelberg University (ZMBH), 69120 Heidelberg, Germany.
Carsten StichtCore Facility Next Generation Sequencing, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0003-3596-6094
Ebtehal El-DemerdashDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.
Kai BreuhahnInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Ahmed Ihab AbdelazizSchool of Medicine, Newgiza University (NGU), Giza 12577, Egypt.
Nada El-EkiabySchool of Medicine, Newgiza University (NGU), Giza 12577, Egypt.ORCID 0000-0002-3393-3873

Funding

Academy of Scientific Research and Technology RESPECT 10037Alexander von Humboldt Foundation EGY-1160930Alexander von Humboldt Foundation EGY-1207096Deutsche Forschungsgemeinschaft grant number 505755359
6 · The paper itself

Abstract

Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are key regulators of hepatic stellate cell (HSC) activation and liver fibrosis. While the canonical YAP/TAZ-TEAD axis is well-characterized, non-canonical interaction partners and downstream long non-coding RNAs (lncRNAs) that orchestrate fibrogenic programs in HSCs remain undefined. Using BioID and next-generation sequencing (NGS) in LX-2 cells, we identified YAP/TAZ-interactomes and YAP/TAZ-regulated lncRNAs. BioID results and proximity ligation assay (PLA) identified the transcription factor Kaiso as a TAZ interaction partner. Functionally, Kaiso knockdown suppressed key aspects of HSC activation in LX-2 cells. We next integrated our NGS results from YAP/TAZ-knockdown in LX-2 cells with publicly available Kaiso ChIP-seq data. This identified HIF1A-AS3 as a common downstream lncRNA. ChIP-qPCR confirmed direct binding of Kaiso to the

Indexed as

Hepatic Stellate CellsHypoxia-Inducible Factor 1, alpha SubunitRNA, Long NoncodingTranscription FactorsAcyltransferasesCell LineGene Expression RegulationHumansLiver CirrhosisProtein BindingTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsAcyltransferasesHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitRNA, Long NoncodingTAFAZZIN protein, humanTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsWWTR1 protein, humanhepatic stellate cellsHIF1A-AS3Hippo signaling pathwayKaisoliver fibrosislong non-coding RNAtranscriptional coactivator with PDZ-binding motifyes-associated protein

Identifiers

PMID42737752
PMCPMC13566411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.